Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Alnylam Pharmaceuticals (ALNY) PT Raised to $193 at Stifel Following Results
August 3, 2021 10:51 AM EDTStifel analyst Paul Matteis raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $193.00 (from $178.00) while maintaining a Buy rating following Q2 results.
The analyst commented, "We are reiterating our Buy rating and we're raising our numbers and target price on 2Q beats,... More
Alnylam Pharma (ALNY) Tops Q2 EPS by 30c
August 3, 2021 8:03 AM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.30), $0.30 better than the analyst estimate of ($1.60). Revenue for the quarter came in at $220.1 million versus the consensus estimate of $193.18 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More